Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

Yoshiya TanakaFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan, Correspondence[email protected]

Hisashi YamanakaInstitute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan,

Tsutomu TakeuchiDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Keio University, Tokyo, Japan,

Makoto InoueInoue Hospital, Gunma, Japan,

Kazuyoshi SaitoFirst Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Japan,

Yukihiko SaekiNHO Osaka Minami Medical Center, Osaka, Japan,

Sang Joon LeeData Center, Product Development, Celltrion, Inc., Incheon, Republic of Korea,

Yoshihiro NambuPharmaceuticals Group, Nippon Kayaku Co., Ltd., Tokyo, Japan

show all

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

Supplementary Appendix

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab

Supplementary Appendix

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date